Physician profile
Beriah Rf Zigler
NPI 1801670930
$4,133.81
in general payments reported to CMS, 2019-2025
26 companies · $2,782 in 2025
The $2,782 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $19.77 · 2024: $1,332 · 2025: $2,782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,123 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,122.52 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $704.16 | 2024-2025 | |
| Corcept Therapeutics | $441.30 | 2024-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $409.31 | 2024-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $367.47 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $342.08 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $282.26 | 2024-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Teva Pharmaceuticals USA, INC. | $220.94 | 2024-2025 | Austedo Xr, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $181.51 | 2024 | |
| Axsome Therapeutics, INC. | $160.50 | 2024-2025 | Auvelity |
| Pfizer INC. | $136.31 | 2024-2025 | |
| Lundbeck LLC | $119.62 | 2025 | Rexulti, Vyepti |
| Harmony Biosciences LLC | $97.41 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $88.49 | 2023-2025 | Rexulti |
| Novo Nordisk INC | $87.77 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $65.13 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $63.63 | 2024-2025 | Evenity, Repatha, Otezla |
| Daiichi Sankyo INC. | $57.80 | 2025 | Injectafer |
| Verona Pharma, INC. | $53.57 | 2025 | Ohtuvayre |
| Aimmune Therapeutics, INC. | $50.17 | 2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $39.20 | 2024-2025 | Voquezna |
| Alnylam Pharmaceuticals INC. | $35.81 | 2025 | Onpattro |
| Janssen Pharmaceuticals, INC | $35.67 | 2024 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.77 | 2024-2025 | Ofev |
| Kyowa Kirin, INC. | $23.12 | 2025 | |
| Glaxosmithkline, LLC. | $21.31 | 2025 | Bexsero, Shingrix, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $14.50 | 2025 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beriah Zigler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.